Intracranial AT RT / radiotherapy. Therapeutic dilemma / radiotherapy
|
|
- Reynold Shelton
- 5 years ago
- Views:
Transcription
1 Therapeutic dilemma / radiotherapy Agressive tumour, poor outcome Past treatments based on MB concepts (RT CSA) MB Overall survival Mean age : 6.52 years n=36, 5 year 75% 1. Tumour occurs in the very young (< 3 years) 2. Requires intensive treatment (high doses of RT / CSA?) 3. Chemotherapy necessary (additional toxicity of RT) AT-RT Mean age : 1.32 years n=19, 5 year 26.3% Koral et al., 2008
2 Survival / radiotherapy - chemotherapy Data base Author Pat. Treatment median age Survival Cleveland Hilden et al., Chx.+ RT (n=13) : 47 mon. Hd. Chx. (+RT) (n=13) : n.a. Chx only (n=29) : n.a. Med. EFS OS 48 mon. 48 mon. 10 mon mon. n.a. Memphis Tekautz et al., Chx.+ RT (n=10) : n.a. (> 3 y.) Chx. Only (n=21) : n.a. (< 3 y.) 2 year EFS 2 year OS 90% 90% 0% 12% HIT Dannenmann- Stern et al., All pat. : 19 mon. Chx.+ RT (n=36) : 37 mon. Chx. Only (n=28) : 10 mon. Med. EFS OS 9 mon. 15 mon. 22 mon. 31 mon. 4 mon. 9 mon. Chen et al., Chx. + RT (n=19) 4.5 y. 11 mon. 17 mon.
3 Open questions 1. Should radiotherapy (XRT) be part of standard therapy in CNS-AT/RT? 2. Where should XRT be placed primary vs salvage therapy? 3. XRT and local tumour control target volume (focal RT vs CSA-RT)? dose prescription (dose-response relationship)?
4 Pattern of relapse / rationale for RT CSA All cases Primary site Primary site and leptomeningeal leptomeningeal Total relapses (46%) 9 (17%) 16 (31%) 49 (94%) Pattern of initial spread / rationale for RT CSA Burger et al., 1998 Parmar et al Rorke et al % : leptomeningeal metastases 33% : leptomeningeal metastases Dannenmann-Stern younger age/ infratent site. : 28.6% M2/3 et al (HIT) older age / supratent. site : 5.6% M2/3
5 Survival after chx / RT CSA Overall survival CSA : Gy Boost : 44-54Gy Total dose 36 Gy / 54 Gy p=0.034 Interval surgery - start of RT p= patients Median age 4.5 y. (2-19 y.) Months after end of RT Chen et al., 2006
6 AT/RT - HIT data base 65 patients (8/1988 8/2004) Follow-up: median 15 mths. (1 109 mths.) Histopathology: 61 / 65 (93.8%) centrally reviewed Data retrospectively collected
7 Patient characteristics HIT data base ( ) All patients ChX - Pat. RT/ChX - Pat. nr gender 41 m / 23 f 16 m / 12 f 25 m / 11 f location infratent. supratent infra-/supratent age at diagnosis (months) 19 (1 170) 10 (1 62) 37 (5 170) age groups 3 yrs. > 3 yrs. 44 (68.8%) 20 (31.2%) low risk (M0/M1) 54 (84.4%) 20 (71.4%) 34 (94.4%) high risk (M2/M3) 10 (16.6%) 8 (28.6%) 2 (5.6%) resection S0 S+ 17 (26.2%) 47 (73.8%) 4 (14.3%) 24 (85.7%) 13 (36.1%) 23 (63.9%)
8 Radiotherapy group (n=36) XRT as primary therapy : n = 19 low risk (M 0/1) n = 18 (95 %) high risk (M 2/3) n = 1 (5 %) all in curative intent (100 %) XRT as salvage therapy : n = 17 in local relapse (M 0/1) n = 14 (82 %) in dissemin. relapse (M 2/3) n = 3 (18 %) 14 / 17 in curative intent (82 %)
9 Radiotherapy / treatment data RT volume focal XRT n = 14 (39 %) 7 x primary RT / 7 x RT at relapse CSA - XRT n = 21 (58 %) 11 x primary RT / 10 x RT at relapse no inf. n = 1 (primary RT) RT dose prescription 33 x conventionally fract. XRT: dose to tumour : med Gy ( ) dose to CSA : med Gy ( ) 2 x hyperfractionated XRT (68 Gy, 72 Gy) 1 x radiosurgery (16 Gy)
10 Radiotherapy / acute toxicity - CTC - Haematological toxicity (CTC grade 3/4): 12 / 33 focal XRT 3 / 12 (25 %) CSA - XRT 9 / 21 (43 %) Neurological toxicitiy (CTC grade 3/4): 1 / 33 1 x SAE (brainstem bleeding at the end of focal XRT)
11 Relapse and survival radiotherapy versus chemotherapy Prim. chx.- pat. : 41 / 44 (93.2%) local (25 = 56.8%), diss. (4), comb (6), M4 (2) no inf. (3) (17 received RT as salvage treatment) Prim. RT-pat. : 10 / 19 (52.6%) local (5 = 26.3%), dissemin. (5) Long - term survival 19 / 64 Pat. (29.7%) survived more than 24 months med. 37 months (24 109) all of them had received XRT (primary / salvage)
12 Progressionfree and overall survival radiotherapy versus chemotherapy Progressionfree survival all pat.: median 9 mths. (1-109) primary chx.: median 4 mths. (1-15) primary XRT : median 22 mths. (3-44) Overall survival all pat.: median 15 mths. (1-109) primary chx: median 9 mths. (2-17) primary XRT: median 31 mths. (2-109)
13 Progressionfree and overall survival / XRT patients Überlebensfunktion Progressionfree survival Überlebensfunktion Overall survival 1,0 1,0,9,9,8,8 Cumulative survival Kum. Überleben,7,6,5,4,3,2,1 0, Überlebensfunktion Survival function Zensiert Cumulative survival Kum. Überleben,7,6,5,4,3,2,1 0, Überlebensfunktion Survival function Zensiert PFS: time from 1.RT until 1. relapse/death (y) OS: time from 1.RT until death (years)
14 Survival / timing of RT 1,0 PFS EFS: : prim.rt RT vs. vssalv.rt RT 1,0 Overall OS : prim. survival: RT vs prim.rt salv. RT vs salv.rt,9,9,8,8 Cumulative survival Kum. Überleben,7,6,5,4,3,2,1 0,0 0 n= 13 n= prim.rt vs salv.rt salv.rt salv.rt-zensiert prim-rt prim-rt-zensiert 10 Cumulative survival Kum. Überleben,7,6,5,4,3,2,1 0,0 0 2 n= 13 n= prim.rt vs. salv.rt salv.rt salv.rt-zensiert prim-rt prim-rt-zensiert 10 PFS: time from 1.RT until 1. relapse/death (y) 2-year-PFS in prim.rt: 53 % +/- 12 % 2-year-PFS in salv.rt: 58 % +/- 14 % Logrank-Test: p= OS: time from 1.RT until death (years) 2-year-OS in prim.rt: 55 % +/- 12 % 2-year-OS in salv.rt: 52 % +/- 14 % Logrank-Test: p=
15 Survival / treatment volume of RT PFS EFS (local disease): loc.rt vs CSI 1,0,9,8 OS OS (local (local disease): loc. loc.rt vs. CSI 1,0,9,8 Cumulative survival Kum. Überleben,7,6,5,4,3,2,1 0,0 0 2 n= 16 n= 14 n= 14 radiation field CSI CSI-zensiert loc.rt loktu-zensiert Cumulative survival Kum. Überleben,7,6,5,4,3,2,1 n= 16 0, radiation field CSI CSI-zensiert loc.rt loc.rt-zensiert 10 PFS: time from 1.RT until 1. relapse/death (y) 2-year-PFS in local RT: 59 % +/- 14 % 2-year-PFS in CSI RT: 46 % +/- 13 % Logrank-Test: p= OS: time from 1.RT until death (years) 2-year-OS in local RT: 54 % +/- 14 % 2-year-OS in CSI RT: 46 % +/- 14 % Logrank-Test: p=
16 Conclusions 1. Primary XRT improved local tumour control better median OS and PFS than primary chx. alone XRT should be part of treatment concept 2. PFS and OS between primary / salvage XRT no significant difference 3. PFS and OS between local / craniospinal XRT no significant difference However : bias in tumour site, age and risk profile Radiotherapy should be part of treatment / open questions optimal sequence optimal treatment volume dose prescription (local / CSA)
17 RT guidelines EUROPEAN RHABDOID REGISTRY / CNS tumours Localized disease supratentorial or infratentorial (M0 according to Chang), age 18 months RT to the extended tumor region according to CT planning. Total dose and fractionation 5 x 1.8 Gy per week, 54.0 Gy PTV acc. to ICRU 50/62. The target volume should include the postoperative or postchemotherapeutic tumor region including potential residual tumor as indicated by CT or T1-T2 MRI following contrast application. A safety margin of 1 cm (= CTV) should be used. Anatomical borders with initial tumor contact need to be included in the planning target volume. The definition of the PTV needs to regard the precision of the technique used. Usually an additional safety margin of 5 mm to 1 cm has to be included.
18 RT guidelines EUROPEAN RHABDOID REGISTRY / CNS tumours Patients with metastatic disease (M1 to M3), age > 18 month to 3 years RT CSA 5 x 1.6 Gy total dose 24.0 Gy. The primary tumour site (not PF in PF tumour sites) total dose of 54.6 Gy, 5 x 1.8 Gy. Boost to spinal deposits Circumscribed solid spinal lesions should be boosted up to 49.2 Gy cumulative dose (for spinal lesions extension according to prior to chemotherapy), 5 x 1.8 Gy. Safety margins in longitudinal extension 1 cm. In diffuse spinal spread up to 35.2 Gy. Boost to intracranial deposits. boosted up to 49.2 Gy cumulative dose, 5 x 1.8 Gy. For children older than 3 years (M1 to M3) RT CSA 5 x 1.6 Gy total dose 35.2 Gy. Boost tumor region 55.0 Gy, 5 x 1.8Gy. Boost to metast deposits : 49.2Gy If tumor persists in a control MRI following 45.0 Gy a boost of the residual disease up to 59.4 Gy can be applied.
19 RT guidelines EUROPEAN RHABDOID REGISTRY / CNS tumours Timing of radiotherapy: Children below the age of 18 months should only be irradiated under exceptional circumstances. We propose a timepoint for RT following immediately after the 4th element of chemotherapy in children 18 months and older. In case of primary metastasized disease RT may be delayed until the end of intensive chemotherapy (following element 9). Other special circumstances may apply such as progressive disease, when RT may be performed at any time (after discussion with the trial coordinator). For infants and children below 18 months radiotherapy may be delayed until age permits or following element 9..
High grade glioma + brainstem glioma
+ brainstem glioma Highly agressive tumours Median survival ca 9-12 months Curative or palliative treatments? Intensity of treatment Side effects Quality of life issues + brainstem glioma Aims of radiotherapy
More informationMedulloblastoma / high risk. Radiotherapy in high risk medulloblastoma
Radiotherapy in high risk medulloblastoma PROS Meeting London 4.-6. October 2012 Reference Centre for Radiotherapy, Dept. for Radiation Oncology University of Leipzig Johannisallee 34, 04107 Leipzig/Germany
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM EPENDYMOMA Last Revision Date July 2015 1 CNS Site Group Ependymoma Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2.
More informationNON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA
NON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA Roberta Rudà Department of Neuro-Oncology University and City of Health and Science Hospital of Turin, Italy EORTC EANO ESMO Conference 2015 Istanbul, March 27-28
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation
More informationPediatr Blood Cancer 2014
Low grade Glioma! 40% of pediatric brain tumors Pathologically, anatomically, clinically and biologically heterogeneous Leptomeningeal metastases in 5% Frequently protracted clinical course Long-Term Outcome
More informationWhere are we with radiotherapy for biliary tract cancers?
Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM GERM CELL TUMOURS CNS Site Group Germ Cell Tumours Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More information8/2/2017. Improving Dose Prescriptions for Safety, Reporting, and Clinical Guideline Consistency. Part III
Improving Dose Prescriptions for Safety, Reporting, and Clinical Guideline Consistency Part III I Das, J Moran, M Langer Keeping Guidelines On Track: The Effect On Clinical Practice of Neglecting Guidelines
More informationProspective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors (SIOPCNSGCTII)
1 von 9 10.12.2013 09:03 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: UKM08_0057 Previous Study Return to List Next Study Prospective Trial for the Diagnosis and Treatment
More informationRadiotherapy and Brain Metastases. Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem
Radiotherapy and Brain Metastases Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem 24-02-2017 Possible strategies Watchful waiting Surgery Postop RT to resection cavity or WBRT postop SRS
More informationSelecting the Optimal Treatment for Brain Metastases
Selecting the Optimal Treatment for Brain Metastases Clinical Practice Today CME Co-provided by Learning Objectives Upon completion, participants should be able to: Understand the benefits, limitations,
More informationWhen is local surgery indicated in metastatic breast cancer?
When is local surgery indicated in metastatic breast cancer? NICOLA ROCHE THE ROYAL MARSDEN HOSPITAL IBCS 2018 Stage at diagnosis 2014 Survival with Stage IV breast cancer Hypothesis Surgical removal of
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM BRAIN METASTASES CNS Site Group Brain Metastases Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM MEDULLOBLASTOMA AND PNET CNS Site Group Medulloblastoma and PNET Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION
More informationCarol Marquez, M.D. Department of Radiation Medicine OHSU
Carol Marquez, M.D. Department of Radiation Medicine OHSU JL is a 8 year old boy who presented with coordination problems in using his right hand (difficulty tying his shoes) in January 2011. Imaging revealed
More informationCNS Metastases in Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer CNS Metastases in Breast Cancer CNS Metastases in Breast Cancer Version 2006: Maass / Junkermann Version 2007 2009: Bischoff
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More informationMinesh Mehta, Northwestern University. Chicago, IL
* Minesh Mehta, Northwestern University Chicago, IL Consultant: Adnexus, Bayer, Merck, Tomotherapy Stock Options: Colby, Pharmacyclics, Procertus, Stemina, Tomotherapy Board of Directors: Pharmacyclics
More informationTarget Delineation in Gliomas. Prof PK Julka Department of Radiotherapy and Oncology AIIMS, New Delhi
Target Delineation in Gliomas Prof PK Julka Department of Radiotherapy and Oncology AIIMS, New Delhi 1 What is a glioma? A primary brain tumour that originated from a cell of the nervous system 2 Recommendations:
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM MENINGIOMA CNS Site Group Meningioma Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION 3 2. PREVENTION
More informationTherapy of Non-Operable early stage NSCLC
SBRT Stage I NSCLC Therapy of Non-Operable early stage NSCLC Dr. Adnan Al-Hebshi MD, FRCR(UK), FRCP(C), ABR King Faisal Specialist Hospital & Research Centre This is our territory Early Stages NSCLC Surgical
More informationTHE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD
THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA TIMUR MITIN, MD, PhD RESECTABLE DISEASE MANAGEMENT: RESECTABLE DISEASE Resection offers the only possibility of long term survival
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More informationMight Adaptive Radiotherapy in NSCLC be feasible in clinical practice?
Might Adaptive Radiotherapy in NSCLC be feasible in clinical practice? E.Molfese, P.Matteucci, A.Iurato, L.E.Trodella, A.Sicilia, B.Floreno, S.Ramella, L.Trodella Radioterapia Oncologica, Università Campus
More informationRadiotherapy of Brain Metastases and Carcinomatous Meningitis
Universitätsspital Basel Radiotherapy of Brain Metastases and Carcinomatous Meningitis Dr. J. Winkler 16.01.2009 1 in 4 cancer patients develop brain metastases In 1/3-1/2 of these patients brain metastasis
More informationA PROSPECTIVE RANDOMISED CONTROLLED TRIAL OF HYPERFRACTIONATED VERSUS CONVENTIONALLY FRACTIONATED RADIOTHERAPY IN STANDARD RISK MEDULLOBLASTOMA
A PROSPECTIVE RANDOMISED CONTROLLED TRIAL OF HYPERFRACTIONATED VERSUS CONVENTIONALLY FRACTIONATED RADIOTHERAPY IN STANDARD RISK MEDULLOBLASTOMA HIT SIOP PNET 4 A SIOP and GPOH TRIAL START DATE 1 st September
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM LOW GRADE GLIOMAS CNS Site Group Low Grade Gliomas Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING
More informationTreatment of Recurrent. Central Nervous System. Primitive Neuroectodermal Tumours (PNETs) in Children and Young People. Version 1.
Treatment of Recurrent Central Nervous System Primitive Neuroectodermal Tumours (PNETs) in Children and Young People Version 1.0 September 2011 Barry Pizer on behalf of the CCLG CNS Interest Group Guidance
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM ANAPLASTIC GLIOMAS CNS Site Group Anaplastic Gliomas Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationSYNOPSIS PROTOCOL N UC-0107/1602
SYNOPSIS PROTOCOL N UC-0107/1602 A) TRIAL IDENTIFICATION SPONSOR PROTOCOL CODE NUMBER: UC-0107/1602 VERSION (NR & DATE): 0.1, MARCH 2016 TRIAL TITLE: Extracranial Stereotactic Body Radiation Therapy (SBRT)
More informationCentral Nervous System Tumors in Children. Dr.Mina Tajvidi
Central Nervous System Tumors in Children. Dr.Mina Tajvidi CNS Central nervous system (CNS) tumors account for 20% to 25% of all malignancies that occur in childhood(united States) The incidence is highest
More informationInstitute of Oncology & Radiobiology. Havana, Cuba. INOR
Institute of Oncology & Radiobiology. Havana, Cuba. INOR 1 Transition from 2-D 2 D to 3-D 3 D conformal radiotherapy in high grade gliomas: : our experience in Cuba Chon. I, MD - Chi. D, MD - Alert.J,
More informationProtons for Head and Neck Cancer. William M Mendenhall, M.D.
Protons for Head and Neck Cancer William M Mendenhall, M.D. Protons for Head and Neck Cancer Potential Advantages: Reduce late complications via more conformal dose distributions Likely to be the major
More informationOptimal Management of Isolated HER2+ve Brain Metastases
Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not
More informationAlleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen?
Department of Radiation Oncology Chairman: Prof. Dr. Matthias Guckenberger Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen? Matthias
More informationDisclosure SBRT. SBRT for Spinal Metastases 5/2/2010. No conflicts of interest. Overview
Stereotactic Body Radiotherapy (SBRT) for Recurrent Spine Tumors Arjun Sahgal M.D., F.R.C.P.C. Assistant Professor Princess Margaret Hospital Sunnybrook Health Sciences Center University of Toronto Department
More informationOncological Management of Brain Tumours. Anna Maria Shiarli SpR in Clinical Oncology 15 th July 2013
Oncological Management of Brain Tumours Anna Maria Shiarli SpR in Clinical Oncology 15 th July 2013 Outline General considerations of Primary Brain Tumours: epidemiology, pathology, presentation. Diagnosis
More informationTreatment Planning Evaluation of Volumetric Modulated Arc Therapy (VMAT) for Craniospinal Irradiation (CSI)
Treatment Planning Evaluation of Volumetric Modulated Arc Therapy (VMAT) for Craniospinal Irradiation (CSI) Tagreed AL-ALAWI Medical Physicist King Abdullah Medical City- Jeddah Aim 1. Simplify and standardize
More informationMehmet Ufuk ABACIOĞLU Neolife Medical Center, İstanbul, Turkey
Updated Oncology 2015: State of the Art News & Challenging Topics CURRENT STATUS OF STEREOTACTIC RADIOSURGERY IN BRAIN METASTASES Mehmet Ufuk ABACIOĞLU Neolife Medical Center, İstanbul, Turkey Bucharest,
More informationCase Report Tackling a Recurrent Pinealoblastoma
Case Reports in Oncological Medicine, Article ID 135435, 4 pages http://dx.doi.org/10.1155/2014/135435 Case Report Tackling a Recurrent Pinealoblastoma Siddanna Palled, 1 Sruthi Kalavagunta, 1 Jaipal Beerappa
More informationFOR PUBLIC CONSULTATION ONLY STEREOTACTIC RADIOSURGERY/ STEROTACTIC RADIOTHERAPY FOR EPENDYMOMA
1 EVIDENCE SUMMARY REPORT FOR PUBLIC CONSULTATION ONLY STEREOTACTIC RADIOSURGERY/ STEROTACTIC RADIOTHERAPY FOR EPENDYMOMA QUESTIONS TO BE ADDRESSED: 1. What is the evidence for the clinical effectiveness
More informationRadiation Therapy for Liver Malignancies
Outline Radiation Therapy for Liver Malignancies Albert J. Chang, M.D., Ph.D. Department of Radiation Oncology, UCSF March 23, 2014 Rationale for developing liver directed therapies Liver directed therapies
More informationFeasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma
Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma ABSTRACT Recurrent or progressive pediatric CNS tumors generally have a poor prognosis
More informationStereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms. Overall Clinical Significance 8/3/13
Stereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms Jason Sheehan, MD, PhD Departments of Neurosurgery and Radiation Oncology University of Virginia, Charlottesville, VA USA Overall
More informationRadiation Therapy for Soft Tissue Sarcomas
Radiation Therapy for Soft Tissue Sarcomas Alexander R. Gottschalk, MD, PhD Assistant Professor, Radiation Oncology University of California, San Francisco 1/25/08 NCI: limb salvage vs. amputation 43 patients
More informationEpendymoma Programme Synopsis
Ependymoma Programme Synopsis TITLE SPONSOR PROTOCOL NUMBER EUDRACT NUMBER NATIONAL INVESTIGATOR- COORDINATOR SIOP Ependymoma program II: An International Clinical Program for the diagnosis and treatment
More informationNeoplasie prostatiche Radioterapia: le nuove strategie
Neoplasie prostatiche Radioterapia: le nuove strategie Dr. PL Losardo U.O.C di Radioterapia Azienda Ospedaliero-Universitaria di Parma Parma, 19.5.2015 VS Very Low risk Low risk Intermediate risk High
More informationBrain metastases: changing visions
Brain metastases: changing visions Roberto Spiegelmann, MD Baiona, 2014 Head, Stereotactic Radiosurgery Unit Dept of Neurosurgery, Chaim Sheba Medical Center Tel Hashomer, Israel The best current estimate
More informationRT in Hodgkin Lymphoma
RT in Hodgkin Lymphoma Lesser is better? Philip Poortmans, M.D. Ph.D. Radiation oncologist Tilburg, The Netherlands Radiation dose in Hodgkin Lymphoma Introduction Current evidence Guidelines 1.0 Early
More informationSacral Chordoma: The Loma Linda University Radiation Medicine Experience. Kevin Yiee MD, MPH Resident Physician
Sacral Chordoma: The Loma Linda University Radiation Medicine Experience Kevin Yiee MD, MPH Resident Physician What is a chordoma? 1 st chordoma discovered in clivus by Virchow and Luschka 1856 Rare tumor
More informationDr. Noelle O Rourke Beatson Oncology Centre, Glasgow RADIOTHERAPY FOR LYMPHOMA???
Dr. Noelle O Rourke Beatson Oncology Centre, Glasgow RADIOTHERAPY FOR LYMPHOMA??? History of Radiotherapy 1895 Rontgen describes X-rays 1896 Becquerel radioactivity 1905 Radiation is used to treat tumours
More informationClinical Case Conference
Clinical Case Conference Palliative radiation therapy for bone metastasis Jeff Burkeen, MD, PGY2 7/20/2015 1 Overview Epidemiology Pathophysiology Common presentations and symptoms Imaging Surgery Radiation
More informationIt s All About Margins. Maaike Milder, Ph.D. Accuray Symposium April 21 st 2018
It s All About Margins Maaike Milder, Ph.D. Accuray Symposium April 21 st 2018 Why margins? The smaller the better! Short Introduction Erasmus MC has been using the CyberKnife Robotic Radiosurgery System
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationEpendymomas: Prognostic Factors and Outcome Analysis in a Retrospective Series of 33 Patients
ORIGINAL ARTICLE Brain Tumor Res Treat 2017;5(2):70-76 / pissn 2288-2405 / eissn 2288-2413 https://doi.org/10.14791/btrt.2017.5.2.70 Ependymomas: Prognostic Factors and Outcome Analysis in a Retrospective
More informationHimmelfarb Health Sciences Library, The George Washington University. Neurology Faculty Publications
Himmelfarb Health Sciences Library, The George Washington University Health Sciences Research Commons Neurology Faculty Publications Neurology 12-2012 Radiation therapy quality in CCG/POG intergroup 9961:
More informationState of the Art Radiotherapy for Pediatric Tumors. Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center
State of the Art Radiotherapy for Pediatric Tumors Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center Introduction Progress and success in pediatric oncology Examples of low-tech and high-tech
More informationClinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221. Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS
Clinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221 Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS 1 Disclosure I have no conflicts of interest to disclose 2 Robotic H&N
More informationOutline. WBRT field. Brain Metastases. Whole Brain RT Prophylactic WBRT Stereotactic radiosurgery (SRS) 1 fraction Stereotactic frame
Radiation Therapy for Advanced NSC Lung Ca Alexander Gottschalk, M.D., Ph.D. Associate Professor Director of CyberKnife Radiosurgery Department of Radiation Oncology University of California San Francisco
More informationJournal of Pediatric Sciences
Journal of Pediatric Sciences Role of post-operative radiation therapy in single brain metastasis from clear cell sarcoma in children: a case report with systemic review Fadoua Rais, Naoual Benhmidou,
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationThe Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D.
The Role of Radiation Therapy in the Treatment of Brain Metastases Matthew Cavey, M.D. Objectives Provide information about the prospective trials that are driving the treatment of patients with brain
More informationNCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18)
BONE (Version 2.2018, 03/28/18) NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) Radiation Therapy Specialized techniques such as intensity-modulated RT (IMRT); particle beam RT with protons, carbon ions,
More informationEffective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,
Ewing Tumor Perez Ewing tumor is the second most common primary tumor of bone in childhood, and also occurs in soft tissues Ewing tumor is uncommon before 8 years of age and after 25 years of age In the
More informationThe technique of craniospinal irradiation of paediatric patients in supine position
The technique of craniospinal irradiation of paediatric patients in supine position Pavel Šlampa 1, Zuzana Seneklova 1, Jiri Simicek 1, Renata Soumarova 1, Petr Burkon 2, Ludmila Burianova 2 1 Masaryk
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cns_embryonal_tumors
More informationEnterprise Interest None
Enterprise Interest None Cervical Cancer -Management of late stages ESP meeting Bilbao Spain 2018 Dr Mary McCormack PhD FRCR Consultant Clinical Oncologist University College Hospital London On behalf
More information4D Radiotherapy in early ca Lung. Prof. Manoj Gupta Dept of Radiotherapy & oncology I.G.Medical College Shimla
4D Radiotherapy in early ca Lung Prof. Manoj Gupta Dept of Radiotherapy & oncology I.G.Medical College Shimla Presentation focus on ---- Limitation of Conventional RT Why Interest in early lung cancer
More informationUpdate on management of metastatic brain disease. Peter Hoskin Mount Vernon Cancer Centre Northwood UK
Update on management of metastatic brain disease Peter Hoskin Mount Vernon Cancer Centre Northwood UK Incidence 15-30% of patients with solid tumours will develop brain metastases Most common primary sites
More informationIGRT Solution for the Living Patient and the Dynamic Treatment Problem
IGRT Solution for the Living Patient and the Dynamic Treatment Problem Lei Dong, Ph.D. Associate Professor Dept. of Radiation Physics University of Texas M. D. Anderson Cancer Center Houston, Texas Learning
More informationThe importance of radiotherapy in paediatric atypical teratoid rhabdoid tumour of the brain
The importance of radiotherapy in paediatric atypical teratoid rhabdoid tumour of the brain Elżbieta KORAB CHRZANOWSKA 1, Joanna BARTOSZEWSKA 2, Monika DROGOSIEWICZ 3, Stanisław KWIATKOWSKI 4, Anna SKOWROŃSKA-GARDAS
More informationAdjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
More informationReirradiazione. La radioterapia stereotassica ablativa: torace. Pierluigi Bonomo Firenze
Reirradiazione La radioterapia stereotassica ablativa: torace Pierluigi Bonomo Firenze Background Stage III NSCLC isolated locoregional recurrence in 25% of pts mostly unresectable; low RR with 2 nd line
More informationSmall and Big Operations: New Tools of the Trade for Brain Tumors. Disclosure. Incidence of Childhood Cancer
Small and Big Operations: New Tools of the Trade for Brain Tumors Nalin Gupta MD PhD Chief, Division of Pediatric Neurosurgery Departments of Neurosurgery and Pediatrics University of California San Francisco
More informationTecniche Radioterapiche U. Ricardi
Tecniche Radioterapiche U. Ricardi UNIVERSITA DEGLI STUDI DI TORINO Should we always rely on stage? T4N0M0 Stage IIIB T2N3M0 Early stage NSCLC The treatment of choice for early-stage NSCLC is anatomic
More informationCarcinoma del retto: Highlights
Carcinoma del retto: Highlights Stefano Cordio Struttura Complessa di Oncologia Medica ARNAS Garibaldi Catania Roma 17 Febbraio 2018 Disclosures Advisory Committee, research funding and speakers bureau
More informationTreating Multiple. Brain Metastases (BM)
ESTRO 36 5-9 May 2017, Vienna Austria, Accuray Symposium Treating Multiple Brain Metastases (BM) with CyberKnife System Frederic Dhermain MD PhD, Radiation Oncologist Gustave Roussy University Hospital,
More informationSBRT in Pancreas Cancer Role of The Radiosurgery Society
SBRT in Pancreas Cancer Role of The Radiosurgery Society Anand Mahadevan MD FRCS FRCR Chairman Division of Radiation Oncology Geisinger Health System, Danville, PA, USA. Past President and Chairman: The
More informationCase Conference: SBRT for spinal metastases D A N I E L S I M P S O N M D 3 / 2 7 / 1 2
Case Conference: SBRT for spinal metastases D A N I E L S I M P S O N M D 3 / 2 7 / 1 2 Case 79 yo M with hx of T3N0 colon cancer diagnosed in 2008 metastatic liver disease s/p liver segmentectomy 2009
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Barcelona October 2017 Interventional radiology and stereotactic radiotherapy Rob Glynne-Jones Mount Vernon Cancer Centre My Disclosures: last 5 years Speaker:
More informationRadiotherapy Protocols
Radiotherapy Protocols Cranial Irradiation for Palliative Whole Brain for Metastases and Prophylactic Whole Brain for SCLC Prepared by: Dr C Blesing, Dr N Warner, Dr D Cutter, Ms R Watson, Ms L Drummond,
More informationPediatrics -Proton Beam Therapy in Children -
Pediatrics -Proton Beam Therapy in Children - Beate Timmermann, M.D. West German Proton Therapy Centre Essen Germany Preview Survival Toxicity Why protons? (theoretically) Experiences so far (clinically)
More informationMini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background
Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016 Background Mostly adenocarcinoma (scc possible, but treated like anal cancer) 39, 220 cases annually Primary treatment: surgery
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationManagement of single brain metastasis: a practice guideline
PRACTICE GUIDELINE SERIES Management of single brain metastasis: a practice guideline A. Mintz MD,* J. Perry MD, K. Spithoff BHSc, A. Chambers MA, and N. Laperriere MD on behalf of the Neuro-oncology Disease
More informationHSV1716 Dose levels and Cohort size Dose level No of Patients HSV1716 Dosage 1* 3 to 6 1 ml of 1 x 10 5 infectious units HSV1716 per ml 2
Abstract and Schema: Description and Rationale: Pediatric high grade gliomas have a progressive initial course and high risk of relapse/ progression; making the 5-year overall survival rate 15-35% with
More informationStereotactic Body Radiotherapy (SBRT) For HCC T A R E K S H O U M A N P R O F. R A D I A T I O N O N C O L O G Y N C I, C A I R O U N I V.
Stereotactic Body Radiotherapy (SBRT) For HCC T A R E K S H O U M A N P R O F. R A D I A T I O N O N C O L O G Y N C I, C A I R O U N I V. Hepatocellular carcinoma (HCC), is a major health problem worldwide.
More informationEvolving of Therapeutic Strategies for CNS-PNET
Evolving of Therapeutic Strategies for CNS-PNET Pediatr Blood Cancer 2013;60:2031 2035 Maura Massimino, MD, 1 * Lorenza Gandola, MD, 2 Veronica Biassoni, MD, 1 Filippo Spreafico, MD, 1 Elisabetta Schiavello,
More informationAdvances in radiation oncology in the management of soft tissue sarcoma 放疗于治疗肉瘤的最新发展
Advances in radiation oncology in the management of soft tissue sarcoma 放疗于治疗肉瘤的最新发展 Brian O Sullivan Bartley-Smith / Wharton Chair Professor, Department of Radiation Oncology The Princess Margaret / University
More information1 Department of Pediatric Hematology and Oncology, University. 3 Department of Pediatrics, University of Erlangen, Erlangen,
Pediatr Blood Cancer 2011;57:978 985 Frequency, Risk-Factors and Survival of Children With Atypical Teratoid Rhabdoid Tumors (AT/RT) of the CNS Diagnosed between 1988 and 2004, and Registered to the German
More informationUpdate on Pediatric Brain Tumors
Update on Pediatric Brain Tumors David I. Sandberg, M.D. Director of Pediatric Neurosurgery & Associate Professor Dr. Marnie Rose Professorship in Pediatric Neurosurgery Pre-talk Questions for Audience
More informationSalvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK
Salvage HDR Brachytherapy Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK Disclosures Still No financial disclosures! Limited personal experience of HDR Brachy as salvage option
More information-Proton Beam Therapy in Paediatric Radiation Oncology -
-Proton Beam Therapy in Paediatric Radiation Oncology - Beate Timmermann, M.D. West German Proton Therapy Centre Essen Germany Preview Survival Toxicity Why protons? (theoretically) Experiences so far
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationSelected radiosurgery cases from the Rotating Gamma Institute Debrecen, Hungary
Selected radiosurgery cases from the Rotating Gamma Institute Debrecen, Hungary László Bognár M.D., Ph.D., József G. Dobai M.D., Gábor Csiky and Imre Fedorcsák M.D., Ph.D. Department of Neurosurgery, Medical
More informationAdvances in external beam radiotherapy
International Conference on Modern Radiotherapy: Advances and Challenges in Radiation Protection of Patients Advances in external beam radiotherapy New techniques, new benefits and new risks Michael Brada
More informationNew modalities in the salvage of recurrent nasopharyngeal carcinoma
New modalities in the salvage of recurrent nasopharyngeal carcinoma Dr Jeeve Kanagalingam FRCS Eng (ORL-HNS) Department of Otorhinolaryngology Tan Tock Seng Hospital SINGAPORE Nasopharyngeal carcinoma
More information